Lipocine
LPCN
24 hedge funds and large institutions have $2.4M invested in Lipocine in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 24 closing their positions.
72,000% more call options, than puts
Call options by funds: $721K | Put options by funds: $1K
2.16% less ownership
Funds ownership: 11.32% → 9.17% (-2.2%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
47% less funds holding
Funds holding: 45 → 24 (-21)
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 24
100% less capital inflows, than outflows
Capital inflows: $23.4K | Capital outflows: $14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.5K |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$2.19K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$1.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$381 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$42 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP Wealth Advisors
Torrance,
California
|
-$13.4M |
| 2 |
Wealth Effects
Boston,
Massachusetts
|
-$71.7K |
| 3 |
Millennium Management
New York
|
-$59K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$51.1K |
LPCN Hedge Fund Activity: Q2 2023 in Review
24 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2023, worth a combined $2.4M — down 86% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LPCN and 3 opened new positions — a net loss of 21 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $19.5K. The largest seller was EP Wealth Advisors, exiting entirely with an estimated $13.4M sold.
- 24 institutional investors held Lipocine (LPCN) as of Q2 2023, down from 45 in Q1 2023.
- Funds reported $2.4M of Lipocine stock for Q2 2023, down 86% quarter-over-quarter.
- 3 funds opened new Lipocine positions in Q2 2023 and 24 closed out, a net change of -21 holders.
- The largest Lipocine buyer in Q2 2023 was Susquehanna International Group, an estimated $19.5K added.
- The largest Lipocine seller in Q2 2023 was EP Wealth Advisors, an estimated $13.4M sold.
Based on aggregated 13F filings for Q2 2023.